Clinical Trials in Tennessee

Showing 18201-18220 of 20,239 trials

Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms

NCT00666926

Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase (FAK) inhibitor PF-00562271 in patients with positive Positron Emission Tomography \[PET\] scans due to advanced non-hematologic malignancies, including pancreatic, head and neck, and prostatic neoplasms, and patients with other malignancies appropriate for serial biopsy. Screening consists of a Fluorodeoxyglucose Positron Emission Tomography \[FDG-PET\] and tumor imaging, medical history, physical examination, Eastern Cooperative Oncology Group \[ECOG\] performance status, blood draws, a pregnancy test for female patients of childbearing potential. Treatment consists of PF00562271 tablets continued until progression of disease, unacceptable toxicity, or patient request. Evaluations for bioactivity are measured by serial FDG-PET and blood tests for biomarkers related to FAK and PYK2 kinase activities.

Head and Neck NeoplasmProstatic NeoplasmPancreatic Neoplasm

Verastem, Inc.99 participantsStarted Dec 2005

Aurora, Colorado, United States • Nashville, Tennessee, United States • East Melbourne, Victoria, Australia +1 more locations

UNKNOWN29 miles

Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project

NCT01815879

Investigator initiated multi-institutional retrospective review of clinical and radiographic outcomes after 90Y resin microsphere radioembolization for metastatic colorectal liver metastases in the USA. The target is for at least 1,000 evaluable patients with 12+ weeks follow up.

Colorectal CancerLiver Metastases

Andrew Kennedy1,000 participantsStarted Dec 2012

Nashville, Tennessee, United States

COMPLETEDPhase 229 miles

A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer

NCT00951613

The purpose of this study is to determine whether NK012 is safe and effective in the treatment of relapsed small cell lung cancer.

Small Cell Lung Cancer

Nippon Kayaku Co., Ltd.72 participantsStarted Jul 2009

Nashville, Tennessee, United States

Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms

Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project

A Study of NK012 in Patients With Relapsed Small Cell Lung Cancer

Find Trials by Condition in Tennessee

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

Phase I Study of ZD4054 (Zibotentan) and Docetaxel in Patients With Metastatic HRPC

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy

INFUSE® Bone Graft/ PEEK Interbody Spacer/ Anterior Cervical Plate Pivotal Clinical Trial

The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4

Evaluation of Vitrase as a Spreading Agent

Irinotecan in Treating Patients With Solid Tumors or Lymphoma Who Have Abnormal Liver or Kidney Function or Who Have Received Radiation Therapy to the Pelvis

Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

A Open-label Food Effect Study With SEN0014196 in Subjects With Huntington Disease

Study of a JAK3 Inhibitor for the Prevention of Acute Rejection in Kidney Transplant Patients

Efficacy of Esomeprazole in Patients With Frequent Heartburn

Ginkgo Biloba Prevention Trial in Older Individuals

A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte

Citalopram to Enhance Cognition in HD

CP-751,871 Treatment For Patients With Multiple Myeloma